Several studies have found an association between high
plasminogen activator inhibitor-1 (PAI-1) levels and
myocardial infarction. Whether this is causal or a consequence of
atherosclerosis or tissue damage, remains unclear. Homozygous carriers of the 4G allele of the 4G/5G polymorphism in the
PAI-1 gene have higher
PAI-1 levels compared to carriers of the 5G allele in healthy persons in some studies, but not all. If
PAI-1 levels are causally related to
myocardial infarction, one would expect more homozygous carriers of the 4G allele among patients, provided that these carriers have high
PAI-1 levels among healthy persons in that population. We investigated the distribution of this polymorphism in the "Study of
Myocardial Infarctions Leiden" (SMILE), including 331 men with a
myocardial infarction and 302 control subjects and measured
PAI-1 antigen levels among the latter. Secondly, we looked into the association of cardiovascular risk factors with
PAI-1 levels. We did not find an increase in risk of
myocardial infarction in carriers of the 4G allele. Neither did we find an association, nor a trend, between the 4G/5G polymorphism and
PAI-1 antigen levels in control subjects. Controls with
obesity,
hypertension, or who smoked had significant higher
PAI-1 antigen levels compared with persons without these factors. High
cholesterol and
triglyceride levels were also associated with high
PAI-1 antigen levels, and
HDL-cholesterol levels showed an inverse association. We conclude that the 4G/5G polymorphism in the
PAI-1 gene is not associated with the risk of
myocardial infarction. As we did not find any association between this polymorphism and
PAI-1 antigen levels in healthy persons, we cannot draw any conclusions about the causality of
PAI-1 itself for
myocardial infarction.